¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"gray platelet syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¿µ¹® congenital rubella syndrome ÇÑ±Û ¼±ÃµÇ³ÁøÁõÈıº
¼³¸í   
  ÀӽűⰣ Áß¿¡ »ê¸ð°¡ Ç³Áø¿¡ °É¸®¸é À̠dzÁø ¹ÙÀÌ·¯½º´Â Å¹ÝÀ» ÅëÇØ¼­ Å¾ƿ¡°Ô Àü´ÞµÇ¾î¼­ Å¾ÆÀǠdzÁø°¨¿°À» ÀÏÀ¸Å²´Ù. ÀӽŠù 3°³¿ù µ¿¾È, Æ¯È÷ ÀӽŠù´Þ¿¡ Å¾ư¡ Ç³ÁøÀÇ °¨¿°À» ¹ÞÀ¸¸é, ½Å»ý¾Æ¿¡¼­ ¼±Ãµ±âÇü, Áï ´«¿¡¼­ ÃÐÁ¡À» Á¤È®È÷ ¸ÂÃß¾îÁִ ·»ÁîÀÇ ¿ªÇÒÀ» Çϴ ¼öÁ¤Ã¼ÀǠȥŹ(¹é³»Àå), ½ÉÀå±âÇü, ±Í¸Ó°Å¸® ¹× ½ÉÇÑ Áö´É¹Ú¾àÀ» µ¿¹ÝÇϴ ¼ÒµÎÁõ µîÀÌ ¹ß»ýÇϴ ¼ö°¡ ¸¹´Ù.
¿µ¹® carpal tunnel syndrome ÇÑ±Û ¼Õ¸ñ±¼ÁõÈıº
¼³¸í   
  ¼Õ¸ñ¿¡´Â ¾ÆÈ© °³ÀÇ ÈûÁÙ°ú ÇÑ °³ÀÇ ½Å°æÀÌ Åë°úÇϴ ±¼ÀÌ Àִµ¥ À̰÷À» ¼Õ¸ñ±¼À̶ó Çϰí, À̰÷À» Áö³ª´Â ½Å°æÀÌ ´­¸®¸é »õ±ú¼Õ°¡¶ôÀ» Á¦¿ÜÇÑ ³× ¼Õ°¡¶ôÀÌ ¾ÆÇÁ°í Àú¸° Áõ»óÀÌ´Ù. À̰ÍÀ» ¼Õ¸ñ±¼ÁõÈıºÀ̶ó ÇÑ´Ù. °Ë»ç ¹æ¹ýÀ¸·Î´Â ±ÙÀ° °Ë»ç¿Í ½Å°æÀü´Þ°Ë»ç°¡ ÀÖ´Ù. ½ÉÇÒ ¶§´Â ¾ÆÄ§À̳ª Àú³á¿¡ ¾ÆÆÄ¼­ ÀáÀ» ±ú°í ¼Õ¸ñ»Ó¸¸ ¾Æ´Ï¶ó ¾î±ú±îÁö ¾ÆÇÁ´Ù. ¼Õ¸ñÀ» ±ÁÈ÷°í ÀÖÀ¸¸é ÅëÁõÀÌ ½ÉÇÏ´Ù. ¼Õ¸ñÀ» ¹Ýº¹ÀûÀ¸·Î »ç¿ëÇϴ ¿îÀüÀÚ, °¡Á¤ÁÖºÎ, ¾Ç±â ¿¬ÁÖÀÚ, °øÀå¶óÀÎÀÇ ±Ù·ÎÀÚ, ÄÄÇ»ÅÍ »ç¿ëÀÚ, ¸ñ¼ö°¡ ÇØ´çµÈ´Ù. ¼Õ¹Ù´Ú»À°¡ ±úÁö°Å³ª ³Ñ¾îÁö¸é¼­ ¼Õ¹Ù´ÚÀ¸·Î Â¤¾úÀ» ¶§µµ ¹ß»ýÇϸ砵幰°Ô Áøµ¿Çϴ °ø±¸¸¦ »ç¿ëÇØµµ ³ªÅ¸³ª±âµµ ÇÑ´Ù. ÀÓ»êºÎ, Åëdz, ·ù¸¶Æ¼½º °üÀý¿°, °©»ó»ù ±â´É ÀúÇÏÁõ, ´ç´¢º´ µîÀÌ ÀÖÀ» ¶§ ÀÌ·± Áõ»óÀÌ ¿Ã ¼ö ÀÖ´Ù. ¿©ÀÚ¿¡°Ô ´õ ¸¹°í ÁַΠÀÚÁÖ ¾²´Â ¼Õ¸ñÀÌ ÇØ´çµÈ´Ù. ½ÉÇÒ ¶§´Â ¼Õ¸ñ¿¡ ¶¥ÄḸÇÑ Å©±â·Î ºÎ¾î¿À¸¥´Ù. ´©¸£¸é ¾ÈÀ¸·Î ¾¦ µé¾î°¡±âµµ ÇÏ°í ´Ù½Ã ¿òÁ÷ÀÌ¸é Æ¢¾î³ª¿Â´Ù. ¼Õ¸ñ»À ¿©´ü °³ Áß¿¡ ¹Ý´Þ»À¶ó ºÒ¸®´Â ÀÛÀº»ÀÀÇ Àδ밡 À̿ϵǾý±ä´Ù. ÅëÁõÀ» °¨¼ÒÇϴ ġ·á·Î ºÎ¸ñ, ¾óÀ½ÂòÁú, ÀÌ´¢Á¦, Ç×»ýÁ¦¸¦ »ç¿ëÇϱ⵵ Çϸç ÅëÁõÀÌ °è¼ÓµÇ¸é ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å È£¸£¸óÀ» ¼Õ¸ñºÎ¿¡ ÁÖ»çÇÏ¿© ÅëÁõÀ» ÁÙÀδÙ. ºÎÀÛ¿ëÀ¸·Î´Â Àç¹ß·üÀÌ ³ô´Ù. 
¿µ¹® sudden infant death syndrome ÇÑ±Û ¿µ¾Æ±Þ»çÁõÈıº
¼³¸í   
  ÇÑ »ì ÀÌÇÏÀÇ °Ç°­ÇÑ ¾Æ±â°¡ ¾Æ¹«·± Á¶ÁüÀ̳ª ¿øÀΠ¾øÀÌ °©Àڱ⠻ç¸ÁÇßÀ» °æ¿ì¿¡ ³»¸®´Â Áø´ÜÀÌ´Ù. ÀÌ ÁõÈıºÀº »ýÈÄ 1~4°³¿ù »çÀÌ¿¡ °¡Àå ¸¹ÀÌ ¹ß»ýÇϸç, ´ëºÎºÐ ¹ã 10½Ã¿¡¼­ ¿ÀÀü 10½Ã »çÀÌ¿¡ ¹ß»ýÇÑ´Ù. Á¶»êÇϰųª ºÎ¸ð°¡ Èí¿¬ÀÚÀÏ °æ¿ì, 20¼¼ ÀÌÇÏ »ê¸ðÀÇ ÃÊ»ê, ÀÓ½ÅÀü °Ç°­°ü¸®¿¡ ¼ÒȦÇÑ »ê¸ð¿¡°Ô¼­ Å¾ ¿µ¾Æ¿¡°Ô¼­ ¸¹ÀÌ ¹ß»ýÇÑ´Ù. ÀÌ ÁõÈıºÀ¸·Î »ç¸ÁÇÑ ¿µ¾ÆÀÇ ÇüÁ¦ÀÏ °æ¿ì ÀϹÝÀûÀΠ¿µ¾Æº¸´Ù °É¸± È®·üÀÌ ³ôÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼ºÈ£Èí±âº´À¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù.
¿µ¹® syndrome ÇÑ±Û ÁõÈıº
¼³¸í   
  Áõ»óÀÇ ÁýÇÕ. ¾î¶² Áúº´ÀǠ¡ÈÄÀÇ ÃÑÇÕÀ» ¸»ÇÑ´Ù. ´ë°³ ±× ¿øÀÎÀº ¾Ë ¼ö ¾øÀ¸³ª, Áõ»óÀÌ º¹ÇÕÀûÀ¸·Î ³ªÅ¸³ª°í ÀÌ¿¡ ´ëÇÑ Ä¡·á°¡ ÀÏÁ¤ÇÑ °æ¿ì ÇϳªÀÇ ÁõÈıºÀ¸·Î Ãë±ÞÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • anxiety syndrome
    ºÒ¾ÈÁõÈıº
  • aortic arch syndrome
    ´ëµ¿¸ÆÈ°ÁõÈıº, ´ëµ¿¸Æ±ÃÁõÈıº
  • apallic syndrome
    ´ë³ú°ÑÁú»ó½ÇÁõÈıº, ´ë³úÇÇÁú»ó½ÇÁõÈıº
  • Apert syndrome
    ¾ÆÆä¸£ÁõÈıº
  • Asherman¡¯s syndrome
    ¾Æ¼Å¸¸ÁõÈıº
  • auriculotemporal syndrome
    ±Ó¹ÙÄû°üÀÚÁõÈıº, À̰³ÃøµÎ½Å°æÁõÈıº
  • Ayerza syndrome
    ¾Æ¿¹¸£»çÁõÈıº
  • acquired immune deficiency syndrome
    ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • acquired immunodeficiency syndrome
    ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • acute brain syndrome
    ±Þ¼º³úÁõÈıº
  • acute radiation syndrome
    ±Þ¼º¹æ»ç¼±ÁõÈıº
  • acute respiratory distress syndrome
    ±Þ¼ºÈ£Èí°ï¶õÁõÈıº
  • adrenogenital syndrome
    ºÎ½Å»ý½Ä±âÁõÈıº
  • adult respiratory distress syndrome
    ¼ºÀÎÈ£Èí°ï¶õÁõÈıº
  • advanced sleep phase syndrome
    ÀüÁø¼ö¸éÀ§»óÁõÈıº
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Guillain-Barre syndrome
    (¢¡acute idiopathic polyneuritis) ±Þ¼ºÆ¯¹ß´Ù¹ß½Å°æ¿° , ±Þ¼ºÆ¯¹ß¿©·¯½Å°æ¿°
  • hemolytic uremic syndrome
    ¿ëÇ÷¿äµ¶ÁõÈıº
  • hemorrhagic fever with renal syndrome
    ÃâÇ÷¿­ÄáÆÏÁõÈıº
  • hepatorenal syndrome
    °£ÄáÆÏÁõÈıº
  • irritable bowel syndrome
    °ú¹Î´ëÀåÁõÈıº
  • Kallmann syndrome
    Ä®¸¸ÁõÈıº
  • Klinefelter's syndrome
    Ŭ¶óÀÎÆçÅÍÁõÈıº
  • Korsakoff's syndrome
    ÄÚ¸£»çÄÚÇÁÁõÈıº
  • locked-in syndrome
    °¨±ÝÁõÈıº
  • Mallory-Weiss syndrome
    ¸»·Î¸®¹ÙÀ̽ºÁõÈıº
  • Marfan syndrome
    ¸¶¸£ÆÇÁõÈıº
  • myelodysplastic syndrome
    °ñ¼öÇü¼ºÀÌ»óÁõÈıº
  • nephritic syndrome
    ÄáÆÏ¿°ÁõÈıº
  • nephrotic syndrome
    ÄáÆÏÁõÈıº, ½ÅÁõÈıº
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • acute brain syndrome
    ±Þ¼º³úÁõÈıº
  • acute radiation syndrome
    ±Þ¼º¹æ»ç¼±ÁõÈıº
  • adhesive syndrome
    À¯ÂøÁõÈıº
  • adrenogenital syndrome
    ºÎ½Å¼º±âÁõÈıº
  • adrenosympathetic syndrome
    ºÎ½Å±³°¨½Å°æÁõÈıº
  • advanced sleep phase syndrome
    ÀüÁø¼ö¸éÀ§»óÁõÈıº
  • aeroadaptation syndrome
    Ç×°ø¼øÀÀÁõÈıº
  • alveolar hypoventilation syndrome
    ÆóÆ÷Àúȯ±âÁõÈıº
  • alveolar-capillary block syndrome
    ÆóÆ÷¸ð¼¼Ç÷°üÂ÷´ÜÁõÈıº
  • amnestic syndrome
    ±â¾ï»ó½ÇÁõÈıº
  • amniotic band syndrome
    ¾ç¸·¶ìÁõÈıº
  • anginal syndrome
    Çù½ÉÁõÁõÈıº
  • angioosteohypertrophy syndrome
    Ç÷°ü»ÀºñÈÄÁõÈıº
  • anterior interosseous nerve syndrome
    ¾Õ»À»çÀ̽ŰæÁõÈıº
  • anterior spinal artery occlusion syndrome
    ¾Õô¼öµ¿¸ÆÆó»öÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gray substance
    ȸ»öÁú.
  • gray-scale
    ȸ»öÁ¶
  • pneumonia,gray hepatization
    ȸ»ö°£È­(°£º¯)(üéß䰣ȭ(°£º¯))
  • posterior gray commissure
    µÚȸ»öÁú¸Â±³Â÷
  • MPV => mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • PAF =platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ.
  • PAF= platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼ºÀÎÀÚ.
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • hemorrhagic diathesis,defective platelet function
    Ç÷¼ÒÆÇ±â´É°á¼Õ(úìá³÷ùѦÒöÌÀáß)
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù).
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù)
  • platelet
    Ç÷¼ÒÆÇ
  • platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • platelet adhesion
    Ç÷¼ÒÆÇºÎÂø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gray substance
    ȸ»öÁú.
  • gray-scale
    ȸ»öÁ¶
  • periaqueductal gray substance
    ¼öµµ°üÁÖÀ§È¸»öÁú
  • pneumonia,gray hepatization
    ȸ»ö°£È­(°£º¯)(üéß䰣ȭ(°£º¯))
  • posterior gray commissure
    µÚȸ»öÁú¸Â±³Â÷
  • blood disc =b. platelet
    Ç÷¼ÒÆÇ(Ì´ËÛ̬).
  • blood platelet =thrombocyte
    Ç÷¼ÒÆÇ(úìá³÷ù).
  • direct platelet count
    Á÷Á¢Ç÷¼ÒÆÇ°è»ê(¹ý)(?Ì´ËÛ̬˭Ë×ËÑ).
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • hemorrhagic diathesis,defective platelet function
    Ç÷¼ÒÆÇ±â´É°á¼Õ(úìá³÷ùѦÒöÌÀáß)
  • human platelet antigens=HPA
    ÀÎÇ÷¼ÒÆÇÇ׿ø
  • mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • mean platelet volume=MPV
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • paf(platelet activating factor)
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ(úìá³÷ù üÀàõì×í­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Marfan's syndrome
    ¸¶¸£ÆÎÁõÈıº
  • medial medullary syndrome
    ³»Ãø¿¬¼öÁõÈıº
  • Meniere's syndrome
    ¸Þ´Ï¿¡¸£ÁõÈıº
  • middle lobe syndrome
    Áß¿±ÁõÈıº
  • mucocutaneous lymph node syndrome
    ÇǺÎÁ¡¸·¸²ÇÁÀýÁõÈıº
  • mucocutaneous ocular syndrome
    ÇǺÎÁ¡¸·¾ÈÁõÈıº
  • nephrotic syndrome
    ½ÅÁõÈıº, ³×ÇÁ·Î½Ã½ºÁõÈıº
  • omental adhesion syndrome
    ´ë¸Á¸·À¯ÂøÁõÈıº
  • overlap syndrome
    ÁßøÁõÈıº
  • Pancoast syndrome
    ÆÇÄÚ½ºÆ® ½Åµå·Ò
  • parietooccipital syndrome
    µÎÁ¤¿±Èĵο±ÁõÈıº
  • peutz-Jegher's syndrome
    Æ÷ÀÌÃ÷-¿¹°ÅÁõÈıº
  • PIE syndrome
    È£»ê±¸¼ºÆóħ½ÀÁõÈıº
  • Poland syndrome
    Æú¶õµåÁõÈıº
  • posterior interosseous syndrome
    Èİñ°£ÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CGM central gray matter
GM gastric mucosa; Geiger-Muller [counter]; general medicine; genetic manipulation; geometric mean; gia...
gr grade; graft; grain; gram; gravity; gray; gross
Gy gray
PAG periaqueductal gray [matter]; polyacrylamide gel; pregnancy-associated globulin; proliferation-assoc...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
DPAG dorsal periaqueductal gray matter
MCG midbrain central gray
PAG periaqueductal gray area
PAG periaqueductal gray region
vlPAG ventrolateral periaquaductal gray
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • adaptation syndrome
    ÀûÀÀÁõÈıº, Á¶ÀýÁõÈıº
    »ýü¿¡ ¿Ü·ÂÀÌ °¡ÇØÁö¸é, ºÎ½Å ÇÇÁú°è, ³úÇϼöü°¡ Ȱµ¿ÇÏ¿© ºÎ½Å ÇÇÁú È£¸£¸óÀÌ °ú·® ºÐºñµÇ¾î ¿Ü·Â¿¡ ÀúÇ×Çϴµ¥, ÀÌ È°µ¿ÀÇ Á¤µµ¿¡ µû¶ó °¢Á¾ ÁúȯÀÌ À¯¹ßµÈ´Ù´Â °³³ä.
  • adrenal Cushing's syndrome
    ºÎ½Å Äí½Ì ÁõÈıº
    °úÀ×ÀÇ ÄÚ¸£Æ¼ÄÚÀ̵忡 ÀÇÇØ ³ªÅ¸³ª´Â Áõ»óÀ» ÀÏÄÃÀ¸¸ç ´ë°³ ´çÁú ÄÚ¸£Æ¼ÄÚÀ̵åÀÇ °ú¿ë·®¿¡ ÀÇÇØ »ý±â°í ºÎ½Å ÇÇÁúÀÇ ÄÚ¸£Æ¼ÄÚÀÌµå »ý»ê¿¡ ÀÇÇÑ °æ¿ì´Â µå¹°´Ù. ÀÚ¿¬ ¹ß»ýÀÇ Äí½Ì ÁõÈıºÀº ¼ºÀÎÀÇ °æ¿ì ´ÙÀ½°ú °°Àº °¡´É¼ºÀÌ ÀÖ´Ù. 1
  • adrenal virilizing syndrome
    ºÎ½Å¼º ³²¼ºÈ­ ÁõÈıº
  • adrenogenital syndrome
    ºÎ½Å ¼º±â ÁõÈıº
    1. ºñÁ¤»óÀ¸·Î ´Ù·®ÀÇ ¾Èµå·ÎÁ¨¼ºÀÇ ½ºÅ×·ÎÀ̵å, ƯÈ÷ µðÇÏÀ̵å·Î ¿¡ÇǾȵå·Î½ºÅ×·ÐÀÌ ºÎ½ÅÀ¸·ÎºÎÅÍ ºÐºñµÇ¾î ±× °á°ú ³²¾Æ¿¡¼­´Â Á¶¼÷Áõ, ¿©¾Æ¿¡¼­´Â ³²¼ºÈ­¸¦ ÀÏÀ¸Å²´Ù. °¡Àå ÈçÇÑ ¿øÀÎÀÌ 21?-hydroxylaseÀÇ ¼±Ãµ¼º °áÇÌ. ¸Å¿ì µå¹°°Ô »ý¸íÀ» ÀÒ°Ô µÇ´Â °æ¿ì°¡ Àִµ¥ ÀÌ´Â 2?-dehydroxylaseÀÇ ¿ÏÀü °áÇÌÀÌ ¿øÀÎÀÌ´Ù. 2. ºÎ½Å ÇÇÁúÀÇ ±â´É Ç×Áø¿¡ ÀÇÇÑ ÁõÈıºÀ¸·Î ¿©¼º¿¡¼­´Â ÀϹÝÀûÀ¸·Î Ãâ»ý ½Ã¿¡ °¡¼º ¹ÝÀ½¾ç ³²¼ºÈ­°¡ ÀÖ°í, ³²¼º¿¡¼­´Â ¼ºÀû Á¶¼÷À» º¸À̳ª »ýÈÄ 3-4³â Àü¿¡´Â ÃâÇöÇÏÁö ¾Ê´Â´Ù. À̵é ÀÓ»ó ¼Ò°ßÀº ÄÚ¸£Æ¼¼ÕÀÇ »ý»ê °áÇ̰ú ¾Èµå·Î°ÕÀÇ »ý»ê °úÀ׿¡ ÀÇÇÏ¿© ³ªÅ¸³­´Ù.
  • adrenosympathetic syndrome
    ºÎ½Å ±³°¨½Å°æ ÁõÈıº
    Àϰú¼º °íÇ÷¾Ð, ´ç´¢, ½É¹Ú ±Þ¼Ó, ¾È»öº¯È­, µÎÅë, ±¸±â, ±¸Åä µîÀÇ ¾Æµå·¹³¯¸° Áßµ¶À» ¿¬»óÄÉ ÇÏ´Â ÁõÈıºÀ¸·Î, ºÎ½Å ¼öÁúÀÇ Å©·Ò ģȭ ¼¼Æ÷Á¾¿¡¼­ º¼ ¼ö ÀÖ´Ù.
  • adult respiratory distress syndrome
    ¼ºÀμº È£Èí°ï¶õ ÁõÈıº
    ¿Ü»ó ¸çÄ¥ ÈÄ¿¡ ¹ß»ýÇÏ´Â °©ÀÛ½º·¯¿î Æó °£Áú ¹× ÆóÆ÷ÀÇ ºÎÁ¾. ÀÌ´Â ³ú ¼Õ»ó ȤÀº Àú»ê¼ÒÁõ¿¡ ÀÇÇØ »ý±â´Â °ú°ÝÇÑ ±³°¨½Å°æ°è Ç×Áø ¶Ç´Â ¸ð¼¼Ç÷°ü Åõ°ú¼ºÀÇ Áõ°¡°¡ ¿øÀÎÀ¸·Î »ý°¢µÈ´Ù.
  • aeroadaptation syndrome
    Ç×°ø ¼øÀÀ ÁõÈıº
  • Aicardi's syndrome
    ¿¡Ä«¸£µð ÁõÈıº
    ¿©¾Æ Á¥¸ÔÀÌ¿¡ ³ªÅ¸³ª´Â ÁõÈÄ·Î ³ú·®Ã¼ÀÇ ¹«¹ßÀ°, »ê¹ßÀûÀÎ ¸Æ¶ô¸· ¸Á¸· º´º¯, ±ÙÀ° °æ·Ã°ú ±äÀ强 Á¤½Å °æ·Ã, Á¤½Å ¹ßÀ° Áöü°¡ Ư¡ÀÌ´Ù.
  • Albright-McCune-Sternberg syndrome
    ¾Ëºê¶óÀÌÆ® ¸ÆÄï ½ºÅϹö±× ÁõÈıº
  • Alezzandrini's syndrome
    ¾Ë·¹Àܵ帮´Ï ÁõÈıº
    ÀÏÃø¼ºÀÇ º¯¼º ¸Á¸·¿°¿¡ °âÇÏ¿© °ðÀÌ¾î µ¿Ãø¿¡ ¹é¹Ý ¹× ¹é¸ðÁõÀÌ »ý±â°í ³­Ã»µµ ÀÖÀ» ¼ö ÀÖ´Ù.
  • Alice in Wonderland syndrome
    ÀÌ»óÇÑ ³ª¶óÀÇ ¾Ù¸®½º ÁõÈıº
    ÀÌÀÎÁõ, ½Åü»óÀÇ Àå¾Ö, ½Ã°£ È帧¿¡ ´ëÇÑ Áö°¢ÀÇ º¯È­ ±×¸®°í ±âŸ ¸Á»óÀ̳ª Âø°¢ µîÀ» ³ªÅ¸³»´Â ÀÏÁ¾ÀÇ ¸Á»ó »óÅÂ. Á¤½Å ºÐ¿­Áõ, °£Áúº´, ÆíµÎÅë, ³ú µÎÁ¤¿±ÀÇ Áúȯ, ÃÖ¸é ÀÌÀü »óÅ ¶Ç´Â ȯ°¢Á¦¸¦ »ç¿ëÇßÀ» ¶§ µî¿¡¼­ º¼ ¼ö ÀÖ´Ù.
  • Alport's syndrome
    ¾ËÆ÷Æ® ÁõÈıº
    ÁøÇ༺ °¨°¢ ½Å°æ¼º ³­Ã», ÁøÇ༺ ½Å¿ì½Å¿° ¶Ç´Â »ç±¸Ã¼ ½Å¿°, ¶§·Î´Â ´«ÀÇ Àå¾Ö¸¦ µ¿¹ÝÇÏ´Â À¯Àü¼º ÁúȯÀ¸·Î¼­ »ó¿°»öü¼º ¿ì¼º ÇüÁú·Î À¯ÀüµÈ´Ù.
  • Alström's syndrome
    ¾Ë½ºÆ®·Ý ÁõÈıº
    »ö¼Ò¼º ¸Á¸·¿°°ú ¾ÈÁø, Á¶±â Áß½É¿Í ½Ã·Â »ó½Ç, ³­Ã», ºñ¸¸ ¹× ´ç´¢º´À» ³ªÅ¸³»´Â ¼±Ãµ¼º ÁõÈıº.
  • alveolar hypoventilation syndrome
    ÆóÆ÷ Àúȯ±â ÁõÈıº
  • alveolar-capillary block syndrome
    ÆóÆ÷-¸ð¼¼Ç÷°ü Â÷´Ü ÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
gray wing A prominence in the floor of the inferior fovea of the fourth ventricle that overlies the dorsal motor nucleus of the vagus.
Synonym: trigonum nervi vagi, ala cinerea, ashen wing, gray wing, trigone of vagus nerve, va'gi eminentia.
(05 Mar 2000)
middle gray layer of superior colliculus See: gray layer of superior colliculus.
Molecular layer, term applied to any layer of brain tissue that contains few nerve-cell bodies and is composed largely of terminal arborizations of dendrites and axons; notable examples are the superficial layer (first layer) of the cerebral cortex and the molecular layer of cerebellum.
Synonym: plexiform layer, stratum moleculare.
(05 Mar 2000)
platelet <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels.
Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation.
Synonym: thrombocytes.
(09 Oct 1997)
platelet-activating factor <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis.
It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction.
Synonym: platelet-aggregating factor.
Acronym: PAF
(20 Sep 2002)
platelet activation A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug.
(12 Dec 1998)
platelet actomyosin The contractile protein of platelets, responsible for clot retraction, platelet aggregation, and release of ADP and other biologic amines essential to platelet function.
Synonym: thrombosthenin.
(05 Mar 2000)
platelet adhesiveness The process whereby platelets adhere to something other than platelets, e.g., collagen, basement membranes, microfibrils, or other "foreign" surfaces.
(12 Dec 1998)
platelet-aggregating factor <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis.
It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction.
Synonym: platelet-aggregating factor.
Acronym: PAF
(20 Sep 2002)
platelet aggregation The attachment of platelets to one another. This clumping together can be induced by a number of agents (e.g., thrombin, collagen) and is part of the mechanism leading to the formation of a thrombus.
(12 Dec 1998)
platelet aggregation inhibitors Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
(12 Dec 1998)
platelet aggregation test A test of the ability of platelets to adhere to each other and hence form a haemostatic plug to prevent bleeding; failure to aggregate occurs in several conditions, e.g., thrombasthenia, Von Willebrand's disease, and following administration of aspirin, phenylbutazone, and indomethacin; the test is conducted by quantitating the decrease in turbidity that occurs in platelet-rich plasma following the in vitro addition of one or several platelet-aggregating agents (e.g., ADP, epinephrine, or serotonin).
(05 Mar 2000)
platelet basic protein <protein> Protein that is the precursor of connective tissue activating peptide III and _ thromboglobulin.
(18 Nov 1997)
platelet cofactor I A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs.
(12 Dec 1998)
platelet cofactor II <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
platelet count <haematology> The number of platelets per cubic millimetre of blood. The normal range is 150,000-400,000 platelets per cubic mm. Platelet counts under 10,000 per cubic millimetre place the patient at risk for spontaneous haemorrhage. Platelets are produced in the bone marrow in increased quantities in response to stress.
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gray market
    ȸ»ö½ÃÀå(±¸Çϱâ Èûµç ¹°Ç°À» ºñ½Î°Ô ÆÄ´Â ÇÕ¹ýÀû ¾Ï½ÃÀå)
  • gray matter
    (³úÀÇ)ȸ¹éÁú;Áö·Â
  • gray mullet
    ¼þ¾î !
  • gray power
    ³ëÀÎ ÆÄ¿ö
  • gray sister
    ÇÁ¶õü½ºÄÚȸ ¼ö³à
  • gray squirrel
    ȸ»ö û¼­(ºÏ¹Ì ¿ø»ê)
  • gray whale
    ·¯¹Ù½ºÆ®°í·¡(ÅÂÆò¼§»ê)
  • gray wolf
    =TIMBER WOLF
  • gray zone
    À̵µ Àúµµ ¾Æ´Ñ(»óÅÂ);¾Ö¸ÅÇÑ (¹üÀ§);ȸ»ö Áö´ë(ÀÇ)(¾î´À Ãʰ­´ë±¹ÀÇ ¼¼·ÂÇÏ¿¡ ÀÖ´Â Áö ¾Ö¸ÅÇÑ Áö¿ª)
  • iron gray
    öȸ»öÀÇ
  • iron gray
    öȸ»öÀÇ
  • pearl gray
    ÁøÁÖºû
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á